CTLA4 and neoplasm: Tumor immune dysfunction and exclusion (TIDE), a computational method that mimics the two major mechanisms of tumor immune evasion, has the ability to predict the prognosis of patients with tumors receiving first-line anti-PD1 or anti-CTLA4 therapy (21).